Cetera Investment Advisers Sells 1,338 Shares of Zimmer Biomet Holdings, Inc. $ZBH

Cetera Investment Advisers lessened its position in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 5.6% in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 22,531 shares of the medical equipment provider’s stock after selling 1,338 shares during the quarter. Cetera Investment Advisers’ holdings in Zimmer Biomet were worth $2,055,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also bought and sold shares of the company. Vanguard Group Inc. increased its position in shares of Zimmer Biomet by 0.7% during the 1st quarter. Vanguard Group Inc. now owns 23,052,925 shares of the medical equipment provider’s stock valued at $2,609,130,000 after purchasing an additional 166,763 shares during the last quarter. Dodge & Cox boosted its holdings in shares of Zimmer Biomet by 2.3% in the first quarter. Dodge & Cox now owns 19,564,454 shares of the medical equipment provider’s stock worth $2,214,305,000 after buying an additional 446,018 shares during the last quarter. Geode Capital Management LLC grew its position in Zimmer Biomet by 1.4% during the second quarter. Geode Capital Management LLC now owns 5,124,776 shares of the medical equipment provider’s stock valued at $465,480,000 after buying an additional 69,485 shares during the period. Ameriprise Financial Inc. increased its holdings in Zimmer Biomet by 236.0% during the first quarter. Ameriprise Financial Inc. now owns 4,568,287 shares of the medical equipment provider’s stock valued at $517,039,000 after buying an additional 3,208,596 shares during the last quarter. Finally, JPMorgan Chase & Co. raised its position in Zimmer Biomet by 251.3% in the first quarter. JPMorgan Chase & Co. now owns 2,081,381 shares of the medical equipment provider’s stock worth $235,571,000 after acquiring an additional 1,488,918 shares during the period. 88.89% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In related news, SVP Lori Winkler sold 1,500 shares of the firm’s stock in a transaction on Monday, September 8th. The shares were sold at an average price of $104.15, for a total transaction of $156,225.00. Following the completion of the transaction, the senior vice president directly owned 6,833 shares of the company’s stock, valued at approximately $711,656.95. This trade represents a 18.00% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 1.39% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on the stock. Evercore ISI cut their price objective on shares of Zimmer Biomet from $106.00 to $104.00 and set an “in-line” rating for the company in a research report on Tuesday, October 7th. Weiss Ratings reissued a “hold (c-)” rating on shares of Zimmer Biomet in a report on Wednesday, October 8th. Redburn Partners set a $130.00 price objective on Zimmer Biomet in a research note on Thursday, September 18th. Barclays lowered their price objective on Zimmer Biomet from $112.00 to $105.00 and set an “underweight” rating on the stock in a research report on Wednesday, November 5th. Finally, Wall Street Zen lowered shares of Zimmer Biomet from a “buy” rating to a “hold” rating in a report on Sunday, November 16th. One analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, nine have issued a Hold rating and two have given a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $109.00.

Zimmer Biomet Stock Performance

NYSE:ZBH opened at $97.52 on Friday. The stock has a 50-day moving average price of $96.84 and a 200 day moving average price of $96.80. The stock has a market capitalization of $19.33 billion, a P/E ratio of 23.73, a P/E/G ratio of 2.29 and a beta of 0.67. Zimmer Biomet Holdings, Inc. has a 12-month low of $85.33 and a 12-month high of $114.44. The company has a current ratio of 1.87, a quick ratio of 0.96 and a debt-to-equity ratio of 0.54.

Zimmer Biomet (NYSE:ZBH) last posted its quarterly earnings results on Wednesday, November 5th. The medical equipment provider reported $1.90 earnings per share for the quarter, topping the consensus estimate of $1.88 by $0.02. Zimmer Biomet had a return on equity of 12.76% and a net margin of 10.51%.The business had revenue of $2 billion during the quarter, compared to the consensus estimate of $2.01 billion. During the same period in the prior year, the company posted $1.74 EPS. The firm’s revenue for the quarter was up 9.6% compared to the same quarter last year. Zimmer Biomet has set its FY 2025 guidance at 8.100-8.300 EPS. Equities research analysts forecast that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current fiscal year.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.